Targeted treatments for cirrhosis

Bibliography

• DEPARTMENT OF HEALTH: Annual Report of the Chief Medical Officer (2001).
   Google Scholar
• FRIEDMAN SL, YAMASAKI G, WONG L: Modulation of transforming growth factor 13 receptors of rat lipocytes during the hepatic wound healing response. Enhanced binding and reduced gene expression accompany cellular activation in culture and in vivo. I Biol. Chen]. (1994) 269:10551–10558.
   Google Scholar
• OLASO E, IKEDA K, ENG FJ et al: DDR2 receptor promotes MMP-2-mediated proliferation and invasion by hepatic stellate cells. Clin. Invest. (2001) 108(9):1369–1378.
   Google Scholar
• GACA MD, ZHOU X, ISSA R, KIRIELLA K, IREDALE JP, BENYON RC: Basement membrane-like matrix inhibits proliferation and collagen synthesis by activated rat hepatic stellate cells: evidence for matrix-dependent deactivation of stellate cells. Matrix Biol. (2003) 22:229–239.
   PubMed Web of Science ®Google Scholar
• ROCKEY DC: Hepatic blood flow regulation by stellate cells in normal and injured liver. Sentin. Liver Dis. (2001) 21(3):337–349.
   PubMedGoogle Scholar
• PINZANI M, MILANI S, DE FRANCO R et al.: Endothelin 1 is overexpressed in human cirrhotic liver and exerts multiple effects on activated hepatic stellate cells. Gastroenterology(1996) 110(2):534–548.
   Google Scholar
• ROCKEY DC, CHUNG JJ: Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: endothelial dysfunction in portal hypertension. Gastroenterology (1998) 114(2):344–351.
   PubMed Web of Science ®Google Scholar
• PINZANI M, MARRA F: Cytokine receptors and signalling in hepatic stellate cells. Sentin. Liver Dis. (2001) 21(3):397–416.
   PubMedGoogle Scholar
• MARRA F: Hepatic stellate cells and the regulation of liver inflammation. Hepatol (1999) 31(6):1120–1130.
   Google Scholar
• FRIEDMAN SL: Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. Biol. Chen]. (2000) 275(4):2247–2250.
   Google Scholar
• •An excellent overview of the molecular mechanisms underlying HSC activation during hepatic fibrogenesis.
   Google Scholar
• PARADIS V, DARGERE D, BONVOUST F, VIDAUD M, SEGARINI P, BED OSSA P: Effects and regulation of connective tissue growth factor on hepatic stellate cells. Lab. Invest. (2002) 82(6):767–774.
   PubMed Web of Science ®Google Scholar
• IREDALE JP, BENYON RC, ARTHUR MJ et al.: Tissue inhibitor of metalloproteinase-1 messenger RNA expression is enhanced relative to interstitial collagenase messenger RNA in experimental liver injury and fibrosis. Hepatology (1996) 24(1):176–184.
   PubMed Web of Science ®Google Scholar
• MURPHY FR, ISSA R, ZHOU X et al: Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition: implications for reversibility of liver fibrosis. " Biol. Chem. (2002) 277(13):11069–11076.
   Google Scholar
• CAMERON GR, KARUNARATNE WA: Carbon tetrachloride cirrhosis in relation to liver regeneration. J. Pathol Bacteria (1936) A-42:1–21.
   Google Scholar
• POYNARD T, MCHUTCHINSON J, MANNS M et al.: Impact of pegylated interferon a-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology (2002) 122:1303–1313.
   PubMed Web of Science ®Google Scholar
• ••An important study demonstrating for thefirst time that combination therapy with PEG-IFN and ribavirin significantly reduces fibrosis progression and even reverses cirrhosis in hepatitis C.
   Google Scholar
• IREDALE JP BENYON RC, PICKERING J et al.: Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors.' Clin. Invest. (1998) 102(3):538–549.
   Google Scholar
• •This paper demonstrates the key mechanisms underlying the reversibility of liver fibrosis using a reproducible animal model.
   Google Scholar
• ISSA R, WILLIAMS E, TRIM N et al: Apoptosis of hepatic stellate cells: involvement in resolution of biliary fibrosis and regulation by soluble growth factors. Gut (2001) 48(4):548–557.
   PubMedGoogle Scholar
• WRIGHT MC, ISSA R, SMART DE et al: Gliotoxin stimulates the apoptosis of human and rat hepatic stellate cells and enhances the resolution of liver fibrosis in rats. Gastroenterology(2001) 121:685–698.
   PubMed Web of Science ®Google Scholar
• •Study demonstrating proof-of-concept that HSC pro-apoptotic agents can abrogate fibrosis.
   Google Scholar
• PREUX AM, D'ORTHO MP, BRALET MP, LAPERCHE Y, MAVIER P: Apoptosis of human hepatic myofibroblasts promotes activation of matrix metalloproteinase-2. Hepatology(2002) 36(3):615–622.
   PubMedGoogle Scholar
• KERKVLIET EH, DOCHERTY AJ, BEERTSEN W, EVERTS V: Collagen breakdown in soft connective tissue explants is associated with the level of active gelatinase-A (IVIMP-2) but not with collagenase. Matrix Biol. (1999) 18:373–380.
   PubMed Web of Science ®Google Scholar
• OHUCHI E, IMAI K, FUJII Y, SATO H, SEIKI M, OKADA Y: Membrane Type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules. J. Biol. Chem. (1997) 272:2446–2451.
   PubMed Web of Science ®Google Scholar
• SMART DE, VINCENT KJ, ARTHUR MJ et al.: JunD regulates transcription of the tissue inhibitor of metalloproteinases-1 and interleukin-6 genes in activated hepatic stellate cells. J. Biol. Chem. (2001) 276(26):24414–24421.
   PubMedGoogle Scholar
• IWAMOTO H, SAKAI H, KOTOH K, NAKAMUTA M, NATAWA H: Soluble Arg-Gly-Asp peptides reduce collagen accumulation in cultured rat hepatic stellate cells. " Hepata (1998) 29(5):752–759.
   PubMedGoogle Scholar
• MONTGOMERY AM, REISFELD RA, CHERESH DA: Integrin a133 rescues melanoma cells from apoptosis in three-dimensional dermal collagen. Proc. Natl. Acad. Sci. USA (1994) 91(19):8856–8860.
   PubMed Web of Science ®Google Scholar
• FRIEDMAN SL, ROLL FJ, BOYLES J, ARENSON DM, BISSELL DM: Maintenance of differentiated phenotype of cultured rat hepatic lipocytes by basement membrane matrix. " Biol. Chem. (1989) 264:10756–10762.
   PubMed Web of Science ®Google Scholar
• ISSA R, ZHOU X, TRIM N et al.: Mutation in collagen-1 that confers resistance to the action of collagenase results in failure of recovery from CC14-induced liver fibrosis, persistence of activated hepatic stellate cells, and diminished hepatocyte regeneration. FASEB J. (2003) 17(1):47–49.
   PubMedGoogle Scholar
• •Evidence that failure to degrade Type-1 collagen specifically influences resolution of the fibrotic response, including hepatocyte regeneration.
   Google Scholar
• MATHEW J, HINES JE, JAMES OF, BURT AD: Non-parenchymal cell responses in paracetamol (acetaminophen)-induced liver injury. Hepata (1994) 20(4):537–541.
   PubMedGoogle Scholar
• IMBERT-BISMUT F, RATZUI V, PIERONI L, CHARLOTTE F, BENHAMOU Y, POYNARD T: Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet (2001) 357:1069–1075.
   PubMed Web of Science ®Google Scholar
• •The use of serum fibrosis markers will be increasingly important to evaluate the impact of antifibrotic therapies, obviating the need for serial liver biopsy. This study shows an impressive correlation between serum fibrosis score and histopathological stage.
   Google Scholar
• ROSSI E, ADAMS L, PRINS A et al: Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients. Clin. Chem. (2003) 49:450–454.
   PubMed Web of Science ®Google Scholar
• •The findings of [28] were not supported by [29]. Both papers serve to highlight a rapidly evolving area with, as yet, no clear consensus.
   Google Scholar
• ISSA R, ZHOU X, CONSTANDINOU CM et al.: Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross-linking. Gastroenterology (2004) 126(7):1795–1808.
   PubMed Web of Science ®Google Scholar
• POWELL LW, KERR JF: Reversal of 'cirrhosis' in idiopathic haemochromatosis following long-term intensive venesection therapy. Australas. Ann. Med. (1970) 19:54–57.
   PubMedGoogle Scholar
• SCHILSKY ML, SCHEINBERG IH, STERNLIEB I: Prognosis of Wilsonian chronic active hepatitis. Gastroenterology (1991) 100:762–767.
   PubMed Web of Science ®Google Scholar
• KWEON YO, GOODMAN ZD, DIENSTAG JL et al.: Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B. Br. J. Hepata (2001) 35:749–755.
   PubMedGoogle Scholar
• LAU DT, KLEINER DE, PARK Y, DI BISCEGLIE AM, HOOFNAGLE JH: Resolution of chronic 8 hepatitis after 12 years of interferon a therapy. Gastroenterology (1999) 117:1229–1233.
   PubMed Web of Science ®Google Scholar
• DUFOUR JF, DELELLIS R, KAPLAN MM: Reversibility of hepatic fibrosis in autoimmune hepatitis. Ann. Intern. Med. (1997) 127:981–985.
   PubMed Web of Science ®Google Scholar
• WANLESS IR: Use of corticosteroid therapy in autoimmune hepatitis resulting in the resolution of cirrhosis. Clin. Gastroentera (2001) 32:371–372.
   PubMedGoogle Scholar
• ENOMARD H, GRIMAUD JA: Active and latent collagenase activity during reversal of hepatic fibrosis in murine schistosomiasis. Hepatology(1989) 10:77–83.
   PubMedGoogle Scholar
• HAMMEL P, COUVELAED A, O'TOOLE D et al.: Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct. N Engl. J. Med. (2001) 344:418–423.
   Google Scholar
• NIETO N, GREENWEL P, FRIEDMAN SL: Ethanol and arachidonic acid increase a 2(I) collagen expression in rat hepatic stellate cells overexpressing cytochrome P450 2E1. Role of H202 and cyclooxygenase-2. J. Biol. Chem. (2000) 275(26):20136–20145.
   Google Scholar
• PIETRANGELO A, MONTOSI G, GARUTI C et al.: Iron-induced oxidant stress in nonparenchymal liver cells: mitochondrial derangement and fibrosis in acutely iron-dosed gerbils and its prevention by silybin." Bioenerg. Biomembr. (2002) 34(1):67–79.
   Google Scholar
• RAMBALDI A, GLUUD C: Colchicine for alcoholic and non-alcoholic liver fibrosis and cirrhosis. Cochrane Database Syst. Rev (2001) 3:CD002148.
   Google Scholar
• RYHANEN L, STENBACK F, ALA-KOKKO L, SAVOLAINEN ER: The effect of malotilate on Type III and Type IV collagen, laminin and fibronectin metabolism in dimethylnitrosamine-induced liver fibrosis in the rat. Hepatol (1996) 24(2):238–245.
   Google Scholar
• KEIDING S, BADSBERG JH, BECKER U et al: The prognosis of patients with alcoholic liver disease. An international randomised, placebo-controlled trial on the effect of malotilate on survival. Hepatol (1994) 20(4):454–460.
   Google Scholar
• MATHURIN P, DUCHATELLE V, RAMOND MJ et al.: Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone. Gastroenterology (1996) 110(6):1847–1853.
   PubMed Web of Science ®Google Scholar
• MITCHISON HC, PALMER JM, BASSENDINE ME WATSON AJ, RECORD CO, JAMES OF: A controlled trial of prednisolone treatment in primary biliary cirrhosis. Three-year results. Hepatol (1992) 15(3):336–344.
   Google Scholar
• HARADA H, WAKABAYASHI G, TAKAYANAGI A et al: Transfer of the interleukin-1 receptor antagonist gene into rat liver abrogates hepatic ischaemia-reperfusion injury. Transplantation (2002) 74(10):1434–1441.
   PubMedGoogle Scholar
• BRUCK R, SHIRIN H, HERSHKOVIZ R et al.: Analysis of Arg-Gly-Asp mimetics and soluble receptor of tumour necrosis factor as therapeutic modalities for concanavalin A-induced hepatitis in mice. Gut (1997) 40(1):133–138.
   PubMedGoogle Scholar
• TILG H, JALAN R, KASER A et al.: Anti-tumor necrosis factor-a monoclonal antibody therapy in severe alcoholic hepatitis. " Hepatol (2003) 38(4):419–425.
   PubMed Web of Science ®Google Scholar
• MURIEL P, FERNANDEZ-MARTINEZ E, PEREZ-ALVARES V et al.: Thalidomide ameliorates carbon tetrachloride induced cirrhosis in the rat. Ear: Gastroenterol Hepatol (2003) 15(9):951–957.
   PubMedGoogle Scholar
• THOMPSON K, MALTBY J, FALLOWFIELD J, MCAULAY M, MILLWARD-SADLER H, SHERON N: Interleukin-10 expression and function in experimental murine liver inflammation and fibrosis. Hepatology(1998) 28(6):1597–1606.
   PubMed Web of Science ®Google Scholar
• NELSON DR, LAUWERS GY, LAU JY, DAVIS GI: Interleuldn 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders. Gastroenterology (2000) 118(4):655–660.
   PubMed Web of Science ®Google Scholar
• SUZUKI K, AOKI K, OHNAMI S, YOSHIDA K, KAZUI T, KATO N: Adenovirus-mediated gene transfer of interferon a inhibits hepatitis C virus replication in hepatocytes. Biochem. Biophys. Res. Commun. (2003) 307(4):814–819.
   PubMedGoogle Scholar
• NAZIROGLU M, CAY M, USTUNDAG B, AKSAKAL M, YEKELER H: Protective effects of vitamin E on carbon tetrachloride-induced liver damage in rats. Cell Biochem. Funct. (1999) 17(4):253–259.
   PubMed Web of Science ®Google Scholar
• HOUGLUM K, VENKATARAMANI A, LYCHE K, CHOJKIER M: A pilot study of the effects of d-a-tocopherol on hepatic stellate cell activation in chronic hepatitis C. Gastroenterology (1997) 113(4):1069–1073.
   PubMedGoogle Scholar
• PARES A, PLANAS R, TORRES M, CABALLERIA J, VIVER JM, ACERO D: Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial. J. Hepatol (1998) 28(4):615–621.
   PubMed Web of Science ®Google Scholar
• KARAMAN A, DEMIRBILEK S, SEZGIN N, GURBUZ N, GURSES I: Protective effect of polyunsaturated phosphatidylcholine on liver damage induced by biliary obstruction in rats. Pediatr. Surg. (2003) 38(9):1341–1347.
   Google Scholar
• MATO JM, CAMARA J, FERNANDEZ DE PAZ J et al: S-adenosylmethionine in alcoholic liver cirrhosis: a randomised, placebo-controlled, double-blind, multicentre clinical trial. Hepatol (1999) 30(6):1081–1089.
   Google Scholar
• NIKI T, ROMB OUTS K, DE BLESER P et al.: A histone deacetylase inhibitor, trichostatin A, suppresses myofibroblastic differentiation of rat hepatic stellate cells in primary culture. Hepatology (1999) 29(3):858–867.
   Google Scholar
• BARONI GS, D'AMBROSIO L, CURTO P eta].: Interferon 7 decreases hepatic stellate cell activation and extracellular matrix deposition in rat liver fibrosis. Hepatology (1996) 23(5):1189–1199.
   Google Scholar
• SHI Z, WAKIL AE, ROCKEY DC: Strain-specific differences in mouse hepatic wound healing are mediated by divergent T helper cytokine responses. Proc Nati Acad. Sci. USA (1997) 94(20):10663–10668.
   PubMedGoogle Scholar
• RAGHU G, BROWN KK, BRADFORD WZ et al: A placebo-controlled trial of interferon 7-lb in patients with idiopathic pulmonary fibrosis. Idiopathic pulmonary fibrosis study group. N Engl. I Med. (2004) 350(2):125–133.
   PubMed Web of Science ®Google Scholar
• UEKI T, KANEDA Y, TSUTSUI H et al: Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat. Med. (1999) 5(2):226–230.
   PubMed Web of Science ®Google Scholar
• MIZOBUCHI Y, SHIMIZU I, YASUDA M, HORI H, SHONO M, ITO S: Retinyl palmitate reduces hepatic fibrosis in rats induced by dimethylnitrosamine or pig serum. Hepatol (1998) 29(6):933–943.
   Google Scholar
• JEONG HG, YOU HJ, PARK SJ et al: Hepatoprotective effects of 183-glycyrrhetinic acid on carbon tetrachloride-induced liver injury: inhibition of cytochrome P450 2E1 expression. Pharmacol Res. (2002) 46(3):221–227.
   PubMed Web of Science ®Google Scholar
• STRIKEL F, BRINKHAUS B, KRAHMER N, SEITZ HK, HAHN EG, SCHUPPAN D: Antifibrotic properties of botanicals in chronic liver disease. Hepatogastroenterology (2002) 49(46):1102–1108.
   PubMedGoogle Scholar
• PINZANI M, MARRA F, CALIGIURI A et al.: Inhibition by pentoxifylline of extracellular signal-regulated kinase activation by platelet-derived growth factor in hepatic stellate cells. Br. J. Pharmacol (1996) 119(6):1117–1124.
   PubMedGoogle Scholar
• WINDMEIER C, GRESSNER AM: Pharmacological aspects of pentoxifylline with emphasis on its inhibitory actions on hepatic fibrogenesis. Gen. Pharmacol (1997) 29(2):181–196.
   PubMedGoogle Scholar
• DI SARIO A, BENDIA E, TAFFETANI S et al.: Selective NaVH* exchange inhibition by cariporide reduces liver fibrosis in the rat. Hepatology (2003) 37(2):256–266.
   PubMedGoogle Scholar
• REIF S, WETS B, AEED H et al: The Ras antagonist, farnesylthiosalicylic acid (FTS), inhibits experimentally-induced liver cirrhosis in rats. J. Hepatol (1999) 31(6):1053–1061.
   PubMedGoogle Scholar
• DEMETRI GD, VON MEHREN M, BLANKE CD et al.: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl. J. Med. (2002) 347(7):472–480.
   PubMed Web of Science ®Google Scholar
• WANG YQ, IKEDA K, IKEBE T et al: Inhibition of hepatic stellate cell proliferation and activation by the semisynthetic analogue of fumagillin TNP-470 in rats. Hepatology (2000) 32(5):980–989.
   PubMedGoogle Scholar
• MARRA F, EFSEN E, ROMANELLI RG, CALIGIURI A, PASTACALDI S, BATIGNANI G: Ligands of peroxisome proliferator-activated receptor 7 modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology (2000) 119(2):466–478.
   PubMed Web of Science ®Google Scholar
• CALDWELL SH, HESPENHEIDE EE, REDICK JA, IEZZONI JC, BATTLE EH, SHEPPARD BL: A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am. J. Gastroenterol (2001) 96(2):519–525.
   PubMed Web of Science ®Google Scholar
• •This small study provides clinical support for the use of PPAR-7 agonists and should pave the way for larger clinical trials.
   Google Scholar
• MARRA F, EFSEN E, ROMANELLI RG et al.: Endothelin induced contractility of stellate cells from normal and cirrhotic rat liver: implications for regulation of portal pressure and resistance. Hepatology (1996) 24(1):233–240.
   PubMedGoogle Scholar
• YU Q, SHAO R, QIAN HS, GEORGE SE, ROCKEY DC: Gene transfer of the neuronal NO synthase isoform to cirrhotic rat liver ameliorates portal hypertension. Clin. Invest. (2000) 105(6):741–748.
   Google Scholar
• OKUNO M, AKITA K, MORIWAKI H, KAWADA N, IKEDA K, KANEDA K: Prevention of rat hepatic fibrosis by the protease inhibitor, camostat mesilate, via reduced generation of active TGF-I3. Gastroenterology (2001) 120(7):1784–1800.
   PubMedGoogle Scholar
• GEORGE J, ROULOT D, KOTELIANSKY VE, BISSELL DM: In vivo inhibition of rat stellate cell activation by soluble transforming growth factor 13 Type II receptor: a potential new therapy for hepatic fibrosis. Proc. Natl. Acad. Sci. USA (1999) 96(22):12719–12724.
   PubMedGoogle Scholar
• QI Z, ATSUCHI N, OOSHIMA A, TAKESHITA A, UENO H: Blockade of type 13 transforming growth factor signalling prevents liver fibrosis and dysfunction in the rat. Proc. Natl. Acad. Sci. USA (1999) 96(5):2345–2349.
   PubMedGoogle Scholar
• ARIAS M, SAUER-LEHNEN S, TREPTAU J et al: Adenoviral expression of a transforming growth factor-I31 antisense mRNA is effective in preventing liver fibrosis in bile-duct ligated rats. BMC Gastroenterol (2003) 3(1):29.
   PubMedGoogle Scholar
• DOOLEY S, HAMZAVI J, BREITKOPF K, WIERCINSKA E, SAID HM, LORENZEN J: Smad7 prevents activation of hepatic stellate cells and liver fibrosis in rats. Gastroenterology (2003) 125(1):178–191.
   PubMedGoogle Scholar
• KLAHR S, MORISSEY JJ: The role of vasoactive compounds, growth factors and cytokines in the progression of renal disease. Kidney Int. Sapp]. (2000) 75:S7–S14.
   PubMedGoogle Scholar
• MATSUAKA T, KATORI H, INAGAMI T, FOGO A, ICHIKAWA I: Communication between myocytes and fibroblasts in cardiac remodelling in angiotensin chimeric mice. Clin. Invest. (1999) 103:1451–1458.
   Google Scholar
• JONSSON JR, CLOUSTON AD, ANDO Y et al: Angiotensin-converting enzyme inhibition attenuates theprogression of rat hepatic fibrosis. Gastroenterology (2001) 121:148–155.
   PubMed Web of Science ®Google Scholar
• CAMINO A, GONZALEZ P, PALACIOS L, FERRANDO J, LAGUENS R, SILVA M: Enalapril attenuates liver fibrogenesis in an animal model. Hepatology (2001) 34(4 Pt 2):A936.
   Google Scholar
• PINES M, KNOPOV V, GENINA O, LAVELIN I, NAGLER A: Halofuginone, a specific inhibitor of collagen Type I synthesis, prevents dimethylnitrosamine-induced liver cirrhosis. J. Hepatol (1997) 27(2):391–398.
   PubMedGoogle Scholar
• BRUCK R, GENINA O, AEED H et al: Halofuginone to prevent and treat thioacetamide-induced liver fibrosis in rats. Hepatology (2001) 33(2):379–386.
   PubMedGoogle Scholar
• HELLERBRAND C, JOBIN C, IIMURO Y, LICATO L, SARTOR RB, BRENNER DA: Inhibition of NFicB in activated rat hepatic stellate cells by proteasome inhibitors and an IicB super-repressor. Hepatology (1998) 27(5):1285–1295.
   PubMedGoogle Scholar
• SALGADO S, GARCIA J, VERA J, SILLER F, BUENO M, MIRANDA A: Liver cirrhosis is reverted by urokinase-type plasminogen activator gene therapy. MM. Ther. (2000) 2(6):545–551.
   PubMed Web of Science ®Google Scholar
• WANG J, JIANG W, YANG C, WANG Y, HE B: Effects of antisense tissue inhibitor of metalloproteinase-1 expressing plasmid on pig serum induced rat liver fibrosis. Gastroenterology (2002):M839.
   Google Scholar
• IIMURO Y, NISHIO T, MORIMOTO T, NITTA T, STEFANOVIC B, CHOI SK: Delivery of matrix metalloproteinase-1 attenuates established liver fibrosis in the rat. Gastroenterology (2003) 124(2):445–458.
   PubMed Web of Science ®Google Scholar
• OZAKI I, ZHAO G, MIZUTA T et al: Hepatocyte growth factor induces collagenase (matrix metalloproteinase-1) via the transcription factor Ets-1 in human hepatic stellate cell line. J. Hepatol (2002) 36(2):169–178.
   PubMed Web of Science ®Google Scholar
• MATSUNO Y, IWATA H, UMEDA Y et al.: Hepatocyte growth factor gene transfer into the liver via the portal vein using electroporation attenuates rat liver cirrhosis. Gene Ther. (2003) 10(18):1559–1566.
   PubMedGoogle Scholar
• WILLIAMS EJ, BENYON RC, TRIM N et al.: Relaxin inhibits effective collagen deposition by cultured hepatic stellate cells and decreases rat liver fibrosis in vivo. Gut (2001) 49:577–583.
   PubMed Web of Science ®Google Scholar
• GIMENEZ A, PARES A, ALIE S et al: Fibrogenic and collagenolytic activity in carbon-tetrachloride-injured rats: beneficial effects of zinc administration. Hepatol (1994) 21(3):292–298.
   Google Scholar
• SAILE B, KNITTEL T, MATTHES N, SCHOTT P, RAMADORI G: CD95/CD95L-mediated apoptosis of the hepatic stellate cell. A mechanism terminating uncontrolled hepatic stellate cell proliferation during hepatic tissue repair. Am.j Pathol (1997) 151(5):1265–1272.
   Google Scholar
• OAKLEY F, TRIM N, CONSTANDINOU CM et al: Hepatocytes express nerve growth factor during liver injury: evidence for paracrine regulation of hepatic stellate cell apoptosis. Am. J. Pathol (2003) 163(5):1849–1858.
   PubMed Web of Science ®Google Scholar
• LI L, TAO J, DAVAILLE J et al.: 15-deoxy-Delta 12,14-prostaglandin J2 induces apoptosis of human hepatic myofibroblasts. A pathway involving oxidative stress independently of perwdsome-proliferator-activated receptors. J. Biol. Chem. (2001) 276(41):38152–38158.
   Google Scholar
• FISCHER R, SCHMITT M, BODE JG,HAUSSINGER D: Expression of the peripheral-type benzodiazepine receptor and apoptosis induction in hepatic stellate cells. Gastroenterology (2001) 120(5):1212–1226.
   PubMedGoogle Scholar
• IWAMOTO H, SAKAI H, TADA S, NAKAMUTA M, NAWATA H: Induction of apoptosis in rat hepatic stellate cells by disruption of integrin-mediated cell adhesion. I Lab. Clin. Med. (1999) 134(21):83–89.
   PubMedGoogle Scholar
• OAKLEY F, MANN J, RUDDELL RG, PICKFORD J, WEINMASTER G, MANN DA: Basal expression of IicBa is controlled by the mammalian transcriptional repressor RBP-J (CBF1) and its activator Notchl. J. Biol. Chem. (2003) 278(27):24359–24370.
   PubMedGoogle Scholar
• ABRISS B, HOLLWEG G, GRESSNER AM, WEISKIRCHEN R: Adenoviral-mediated transfer of p53 or retinoblastoma protein blocks cell proliferation and induces apoptosis in culture-activated hepatic stellate cells. Hepatol (2003) 38(2):169–178.
   Google Scholar
• BELJAARS L, MOLEMA G, SCHUPPAN D, GEERTS A, DE BLESER PJ, WEERT B: Successful targeting to rat hepatic stellate cells using albumin modified with cyclic peptides that recognize the collagen Type VI receptor. J. Biol. Chem. (2000) 275(17):12743–12751.
   PubMedGoogle Scholar
• GAO R, MCCORMICK CJ, ARTHUR MJ et al.: High efficiency gene transfer into cultured primary rat and human hepatic stellate cells using baculovirus vectors. Liver (2002) 22(1):15–22.
   PubMedGoogle Scholar
• GARCIA-BANUELOS J, SILLER-LOPEZ F, MIRANDA A, AGUILAR LK, AGUILAR-CORDOVA E, ARMENDARIZ-BORUNDA J: Cirrhotic rat livers with extensive fibrosis can be safely transduced with clinical-grade adenoviral vectors. Evidence of cirrhosis reversion. Gene flier: (2002) 9(2):127–134.
   Google Scholar